These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 3566358)

  • 1. Endocrine and clinical effects of spironolactone in female hyperandrogenism.
    Siegberg R; Ylöstalo P; Laatikainen T; Pelkonen R; Stenman UH
    Arch Gynecol; 1987; 240(2):67-73. PubMed ID: 3566358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a combination of ethinylestradiol and desogestrel in adolescents with oligomenorrhea and ovarian hyperandrogenism.
    Nappi C; Farace MJ; Leone F; Minutolo M; Tommaselli AP; Montemagno U
    Eur J Obstet Gynecol Reprod Biol; 1987 Jul; 25(3):209-19. PubMed ID: 2956138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic studies on desogestrel administered alone and in combination with ethinylestradiol.
    Cullberg G
    Acta Obstet Gynecol Scand Suppl; 1985; 133():1-30. PubMed ID: 3161265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of ovulation with spironolactone (Aldactone) in anovulatory oligomenorrheic and hyperandrogenic women.
    Evron S; Shapiro G; Diamant YZ
    Fertil Steril; 1981 Oct; 36(4):468-71. PubMed ID: 6793406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of a pure anti-androgen (flutamide) on LH, FSH, androgens and clinical status in idiopathic hirsutism.
    Couzinet B; Pholsena M; Young J; Schaison G
    Clin Endocrinol (Oxf); 1993 Aug; 39(2):157-62. PubMed ID: 8370128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
    Azziz R; Black VY; Knochenhauer ES; Hines GA; Boots LR
    J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of hirsutism with spironolactone.
    Cumming DC; Yang JC; Rebar RW; Yen SS
    JAMA; 1982 Mar; 247(9):1295-8. PubMed ID: 7199587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome.
    Falsetti L; Galbignani E
    Contraception; 1990 Dec; 42(6):611-9. PubMed ID: 2150631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose spironolactone in the treatment of female hirsutism.
    Ylöstalo P; Heikkinen J; Kauppila A; Pakarinen A; Järvinen PA
    Int J Fertil; 1987; 32(1):41-5. PubMed ID: 2880814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of monophasic combinations of ethinyl estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: a randomized trial.
    Moutos D; Smith S; Zacur H
    Contraception; 1995 Aug; 52(2):105-9. PubMed ID: 8536446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low dose spironolactone in the treatment of female hyperandrogenemia and hirsutism.
    Vĕtr M; Sobek A
    Acta Univ Palacki Olomuc Fac Med; 1993; 135():55-7. PubMed ID: 7976677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women.
    Holte J; Bergh T; Gennarelli G; Wide L
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):473-81. PubMed ID: 7955458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of effect of spironolactone on hair shaft diameter in hirsute females.
    McLellan AR; Rentoul J; MacKie R; McInnes GT
    Postgrad Med J; 1989 Jul; 65(765):459-62. PubMed ID: 2690044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dexamethasone and spironolactone in the treatment of non-tumorous hyperandrogenism.
    Prezelj J; Kocijancic A; Andolsek L
    Gynecol Endocrinol; 1989 Dec; 3(4):281-8. PubMed ID: 2516705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effects of spironolactone in polycystic ovary syndrome.
    Milewicz A; Silber D; Kirschner MA
    Obstet Gynecol; 1983 Apr; 61(4):429-32. PubMed ID: 6828272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of spironolactone on testosterone fractions and sex-hormone binding globulin binding capacity in hirsute women.
    Marcondes JA; Minanni SL; Luthold WW; Lerário AC; Nery M; Mendonça BB; Wajchenberg BL; Kirschner MA
    J Endocrinol Invest; 1995 Jun; 18(6):431-5. PubMed ID: 7594237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome.
    Adams JM; Taylor AE; Crowley WF; Hall JE
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4343-50. PubMed ID: 15356031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial.
    Azziz R; Ehrmann D; Legro RS; Whitcomb RW; Hanley R; Fereshetian AG; O'Keefe M; Ghazzi MN;
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1626-32. PubMed ID: 11297595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia.
    Futterweit W; Dunaif A; Yeh HC; Kingsley P
    J Am Acad Dermatol; 1988 Nov; 19(5 Pt 1):831-6. PubMed ID: 3192772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.